The Hospital Authority’s latest cancer data revealed that the number of cancer patients in Hong Kong had reached a historical high, with 30,000 new cases in 2015¹ alone. AXA Hong Kong understands that each cancer patient’s recovery period differs and the medical expense is often highly unpredictable, thus creating a heavy financial burden. To further understand patients’ needs, AXA Hong Kong commissioned marketing research firm Nielsen to conduct an online survey² with 1,010 interviewees aged from 18 to 54. The findings revealed that 66% of respondents rely on their personal savings to cover the medical expenses when diagnosed with a critical illness, 54% of those surveyed hope to shorten the waiting period between two cancer claims, and 82% of respondents hope their critical illness product will provide a monthly payout until remission. Additionally, 61% of respondents worry about the high medical expenses after being discharged from hospital following cancer treatment, such as medicine, special therapy and unforeseen requirements.
AXA Hong Kong has designed and introduced a pioneering and comprehensive protection package for over 128 illnesses – the CritiPartner Critical Illness Plan (“CritiPartner”) – with a first-in-the-market "Continuous Cancer Payout Benefit”, including -
“The concept of this new Critical Illness plan originates from a needs analysis of customers and relevant claims data. As a lifelong healthcare partner, AXA Hong Kong walks along a life journey together with our customers, providing support in times of struggle. Among all critical illnesses, cancer is of utmost importance and constitutes 80% of our critical illness claims. It is the core part that critical illness insurance must cover. Medical research statistics reveal that some common types of cancer have a higher rate of relapse which also comes earlier³, whereas for late diagnosis the treatment and recovery period is usually much longer⁴. In view of the long duration of treatment and recovery, we put customers’ insights and needs into the heart of designing of our CritiPartner Critical Illness Plan – a first-in-the-market breakthrough concept of Continuous Cancer Payout Benefit. Patients can flexibly make use of the monthly payout as income replacement to pay for either medical treatment or living expenses,” said Kevin Chor, Chief Life Product and Proposition Officer, AXA Hong Kong.
“Continuous cancer treatment is a long journey and we designed the payout as a form of income replacement, so our customers can have psychological and financial peace of mind and can focus on recovery, and hence reprioritise what matters most in life. What’s more, we have also shortened the waiting period between cancer claims in order to ensure the benefit, for both medical and life, kicks in at the most suitable time during the recovery journey,” added Kevin.
For most of the common critical illness plans in the market, patients diagnosed with cancer will receive lump sum compensation. Patients need a positive diagnosis (continuous or relapse) after waiting for the 3-year waiting period before they can claim another lump sum benefit. Some products in the market pledge to have a 1-year waiting period; however, only a new cancer diagnosis with different malignant cell origin which is unrelated to the first cancer claim, applies. Some products, which also pledge to offer continuous cancer payout benefit, are actually medical reimbursement plans but do not truly support the living expenses of the patients.
Due to the inherent unpredictability of cancer, which in some cases may demonstrate a high probability of relapse at 2 to 3 years⁵, typical lump sum compensation may not sufficiently cover the actual needs of the cancer patients. In this respect, the brand-new "CritiPartner Critical Illness Plan" from AXA Hong Kong responds in a timely way to the real-life needs, concerns and requirements of patients across all of the stages of the recovery journey. Patients can opt for their best-fit: for 3-year-or-above relapse, the traditional lump sum claim applies; for continuous treatment or cancer relapse in 1.5 years, patients can have monthly payout instead so that they can afford timely medical treatment, until the illness is stabilised or is in remission.
Additional features for "CritiPartner Critical Illness Plan"
For more information on the new critical illness protection product, please visit AXA Hong Kong product website for details.
The above information is for reference only. For details of the product features, content, terms, conditions and exclusions, please refer to the relevant product brochures.
Source: Published Data from Hospital Authority in 2017: http://www.pmh.org.hk/haho/ho/pad/171227C.pdf
“AXA Stability and Prosperity Index” conducted between 13 April 2018 to 3 May 2018
 By taking Colorectal Cancer and Breast Cancer as examples.
Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3994626/
Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare: http://cebp.aacrjournals.org/content/21/5/800.full
 Information by National Health Service (UK): http://www.nhsnegligence.co.uk/delayed-diagnosis-or-misdiagnosis/
 Patient Information Website of American Society of Clinical Oncology: https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/follow-care-colorectal-cancer